Elicio Therapeutics reported a net loss of $39.57 million for the full year ended December 31, 2025, improved from $51.9 million in 2024.2
Basic and diluted loss per share was $2.58, compared to $4.25 the previous year.2
Cash and cash equivalents stood at $18.6 million as of December 31, 2025, up from $17.6 million in 2024.3
The company raised $4.9 million in net proceeds in Q4 2025 and $6.3 million in Q1 2026 via at-the-market program.3
Current cash is expected to support operations into Q3 2026, beyond the Phase 2 AMPLIFY-7P trial's primary DFS endpoint analysis in 1H 2026.3
The announcement was made on March 12, 2026.26
Sources:
2. https://www.marketscreener.com/news/elicio-therapeutics-inc-reports-earnings-results-for-the-full-year-ended-december-31-2025-ce7e5fd2d088f621
3. https://intellectia.ai/news/stock/elicio-therapeutics-reports-fy-gaap-eps-and-cash-position